Attached files
| file | filename |
|---|---|
| 8-K - PHARMACYCLICS INC | form8k07380004_11062014.htm |
| 8-K - EXHIBITS 99.2 - 99.9 - PHARMACYCLICS INC | exsto8k07380004_11062014.pdf |
Exhibit 99.1
American Society of Hematology (ASH) Annual Meeting: San Francisco, California; December 6 - 9, 2014
|
Title
|
Presenting Author
|
Presentation Date/Time
|
|
Ibrutinib, Single Agent or in Combination with Dexamethasone, in Patients with Relapsed/Refractory Multiple Myeloma (MM): Preliminary Phase 2 Results
|
Dr. Vij
|
Session Name: Myeloma: Therapy, excluding Transplantation I
Date: Saturday, December 6, 2014
Presentation Time: 12:00 p.m. PT
Location: West Building, 2001-2003-2014-2016
|
|
Complex Karyotype, Rather Than del(17p) Is Associated with Inferior Outcomes in Relapsed or Refractory CLL Patients Treated with Ibrutinib-Based Regimens
|
Dr. Thompson
|
Session Name: CLL: Therapy, excluding Transplantation:
Phase 3 Trials and More
Date: Saturday, December 6, 2014
Presentation Time: 12:45 p.m. PT
Location: South Building, Gateway Ballroom 104
|
|
Mutational Analysis of Patients with Primary Resistance to Single-Agent Ibrutinib in Relapsed or Refractory Mantle Cell Lymphoma (MCL)
|
Dr. Balasubramanian
|
Session Name: Non-Hodgkin Lymphoma: Biology, excluding
Therapy: Genomic
Date: Sunday, December 7, 2014
Presentation Time: 1:15 p.m. PT
Location: South Building, Gateway Ballroom 104
|
|
Functional evidence using deuterated water labeling that the Bruton tyrosine kinase inhibitor ibrutinib inhibits leukemia cell proliferation and trafficking and promotes leukemia cell death in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma
|
Dr. Burger
|
Session Name: CLL: Therapy, excluding Transplantation:
Novel Therapies
Date: Monday, December 8, 2014
Presentation Time: 7:15 a.m. PT
Location: West Building, 3001-3003-3014-3016
|
|
Efficacy and Safety of Ibrutinib in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia with 17p Deletion: Results from the Phase II RESONATE™-17 Trial
|
Dr. O’Brien
|
Session Name: CLL: Therapy, excluding Transplantation:
Novel Therapies
Date: Monday, December 8, 2014
Presentation Time: 7:30 a.m. PT
Location: West Building, 3001-3003-3014-3016
|
|
Combination Of Ibrutinib and BCL-2 or SYK Inhibitors In Ibrutinib Resistant ABC-Subtype Of Diffuse Large B-Cell Lymphoma
|
Dr. Kuo
|
Session Name: Lymphoma: Pre-Clinical – Chemotherapy and Biologic Agents
Date: Monday, December 8, 2014
Presentation Time: 2:45 p.m. PT
Location: West Building, 2005-2007-2018-2020
|
|
Ibrutinib and Rituximab are an Efficacious and Safe Combination in Relapsed Mantle Cell Lymphoma: Preliminary Results from a Phase II Clinical Trial
|
Dr. Wang
|
Session Name: Lymphoma: Therapy with Biologic Agents, excluding Pre-Clinical Models: Aggressive NHL
Date: Monday, December 8, 2014
Presentation Time: 5:00 p.m. PT
Location: South Building, Esplanade 304-306-308
|
|
Ibrutinib Monotherapy in Relapsed/Refractory Follicular Lymphoma (FL): Preliminary Results of a Phase 2 Consortium (P2C) Trial
|
Dr. Bartlett
|
Session Name: Lymphoma: Therapy with Biologic Agents, excluding Pre-Clinical Models: Indolent B-cell NHL and T-cell NHL
Date: Tuesday, December 9, 2014
Presentation Time: 7:45 a.m. PT
Location: West Building, 2005-2007-2018-2020
|